title: Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.
authors.forename: Wedad M
authors.initials: WM
authors.lastname: Hanna
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hammond
authors.forename: Clive R
authors.initials: CR
authors.lastname: Taylor
authors.forename: David J
authors.initials: DJ
authors.lastname: Dabbs
authors.forename: Frederique
authors.initials: F
authors.lastname: Penault-Llorca
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Bloom
authors.forename: Michael
authors.initials: M
authors.lastname: Bilous
authors.forename: Sunil
authors.initials: S
authors.lastname: Badve
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis*; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods / Q000592:standards; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D017410:Practice Guidelines as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases